Before revision: While numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers have already been used at some point in patient care; including, AFP ( Liver Cancer ), BCR-ABL ( Chronic Myeloid Leukemia ), BRCA1 / BRCA2 ( Breast / Ovarian Cancer ), BRAF V600E ( Melanoma / Colorectal Cancer ), CA-125 ( Ovarian Cancer ), CA19.9 ( Pancreatic Cancer ), CEA ( Colorectal Cancer ), EGFR (Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT ( Gastrointestinal stromal tumor), PSA ( Prostate Specific Antigen) (Prostate Cancer ), S100 ( Melanoma ), and many others.
After revision: While numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers have already been used at some point in patient care; including, AFP ( liver cancer ), BCR-ABL ( chronic myeloid leukemia ), BRCA1 / BRCA2 ( breast / ovarian cancer ), BRAF V600E ( melanoma / colorectal cancer ), CA-125 ( ovarian cancer ), CA19.9 ( pancreatic cancer ), CEA ( colorectal cancer ), EGFR (Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT ( gastrointestinal stromal tumor), PSA ( prostate specific antigen) (prostate cancer ), S100 ( melanoma ), and many others.